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ABSTRACT 
 
Background: To compare the efficiency of dorzolamide + timolol fixed 
combination vs. the Brimonidine + timolol fixed combination in the management 
of primary open-angle glaucoma Materials and methods: A prospective study 
conducted over a period of 6 months with a total of 69 patients having primary open 
angle glaucoma (POAG) who completed a follow up of 6 months at a tertiary care 
hospital. Detailed history of the patient was obtained and patients were assessed for 
best corrected visual acuity, base line IOP with Goldmann applanation tonometer and 
detailed anterior and posterior segment examination. They were categorized into two 
groups according to the combinations prescribed by the ophthalmologist as follow: 
group 1-dorzolamide+timolol and group 2-brimonidine+timolol. A follow up 
evaluation of each patient was done at 1, 3 and 6 months after baseline visit. Results: 
During our study the baseline IOP for dorzolamide + timolol group was 25.7 ±4.25 mm 
Hg and for brimonidine + timolol group was 26.3 ±5.86 mm Hg. During 6 months 
treatment, the mean reduction in IOP was 7.83 mm Hg (29.4%) in dorzolamide + 
timolol group and 9.39 mm Hg (35.6%) in brimonidine + timolol group. Conclusion: Our 
study showed that brimonidine + timolol combination has superiority over 
dorzolamide + timolol to reduce the IOP in newly diagnosed patients with POAG The 
value of IOP reduction in our study in brimonidine + timolol group was 9.39 mm Hg 
(35.6%) and 7.83 mm Hg (29.4%) in dorzolamide + timolol group.  
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INTRODUCTION 
Glaucoma is a group of disorders characterized by progressive 
optic neuropathy resulting in characteristic appearance of 
optic disc and specific pattern of visual field defects that are 
associated frequently but not invariably with raised intra 
ocular pressure (IOP). Glaucoma affects as many as 67 million 
people worldwide and is a leading cause of vision loss and 
blindness[1]. Normal IOP ranges between 10-20 mm Hg. The 
aetiology of glaucoma is multi factorial, but, to date, reduction 
of intraocular pressure (IOP) is the only evidence-based 
therapy for glaucoma.  
POAG (primary open angle glaucoma) results due to decrease 
in the aqueous outflow facility due to increased resistance to 
aqueous outflow as a result of thickening and sclerosis of 
trabecular meshwork, narrowing of inter trabecular spaces 
and deposition of amorphous material in juxtra canalicular 
space[2]. It is characterized by slowly progressive raised 
intraocular pressure (IOP), open appearing anterior chamber 
angle, characteristic optic disc cupping and specific visual field 
defects [3]. 
IOP reduction is achieved by the use of topical medications. 
Fixed combinations of IOP-lowering medications have been 
developed by combining different pharmacologic classes of 
ocular hypotensive drugs commonly prescribed for the 
treatment of elevated IOP in patients affected by open-angle 
glaucoma or ocular hypertension[4,5]. Modern fixed 
combinations pair beta-adrenoceptor antagonists (beta-
blocker) with either prostaglandin analogues or carbonic 
anhydrase inhibitors or alpha adrenergic agonists[6]. Potential 
benefits of fixed combinations include better compliance, 
reduction in exposure to preservatives, and elimination of the 
washout effect.  
Vision lost as a result of glaucoma cannot be recovered. The 
goal of treatment therefore is      to prevent further optic nerve 
and visual field damage by adequately lowering the IOP. An 
approach to the treatment of primary open angle glaucoma is 
outlined below: 
Counsel the patient: on the nature and natural history of 
disease, drug compliance and probability of life time 
treatment. 
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Define target IOP: usually at least 20% reduction from the 
baseline IOP; target IOP should     be lower if there is advanced 
damage or if the disease continues to progress[7]. 
Aim: To compare the efficiency of dorzolamide + timolol fixed 
combination vs. the brimonidine + timolol fixed combination 
in the management of primary open-angle glaucoma.  
MATERIALS & METHODS  
Study design: A prospective analytical study  
Ethical approval: The study was approved by the IRB and 
patients fulfilling the selection criteria were enrolled and 
written informed consent was taken. 
Sample size: A total of 69 patients with POAG completed a 
follow up of 6 months at a tertiary care hospital.  
Inclusion criteria: The population comprised of men and 
women above the age of 15 years. It included patients 
diagnosed as having glaucoma and on anti-glaucoma 
medications. 
Exclusion criteria: Those with a history of ocular inflammation 
or infection within last 3 months of baseline, known to be 
sensitive to vehicle or drug, pregnant or lactating women 
psychiatric patients, patients younger than 15 years and those 
who refused to participate were excluded from the study. 
Grouping: They were categorized into two groups according to 
the combinations prescribed by the ophthalmologist as follow: 
group 1: Dorzolamide + timolol (n=35) and Group 2: 
Brimonidine + timolol (n=34).  
Drug administration: Eye drops twice a day. 
Methodology: Detailed history of the patient was obtained 
and recorded in a pre-tested Case Record Form along with 
findings from general examination, laboratory investigations, 
if any, and treatment given. All patients were assessed for best 
corrected visual acuity, base line IOP with Goldmann 
applanation tonometry, angle grading with gonioscopy, 
detailed anterior and posterior segment examination. 
A follow up evaluation of each patient was done at 1, 3 and 6 
months after baseline visit. At each subsequent visit, IOP 
measurement and direct ophthalmoscopy was repeated. 
Efficacy was assessed by the degree of reduction in intraocular 
pressure and change in cup disc ratio. Additionally, the 
patients were asked for adverse drug reactions (ADRs), if any, 
and the details were noted in an ADR reporting form[8-10]. 
Statistical analysis: Analyses were performed for both the 
groups of group 1 & group 2 [11,12]. Analysis of variance 
(ANOVA) was used to test between-group differences in mean 
IOP at baseline and analysis of covariance (ANCOVA) with 
baseline IOP as the covariate was used to test between group-
differences in mean IOP at follow-up visits. Results were 
qualitatively similar when ANOVA rather than ANCOVA was 
used for these analyses. Other continuous variables were 
analyzed using t-tests. Categorical variables were analyzed 
using the chi-square test. All statistical tests were two-tailed 
with the level for significance set at 0.05. 
RESULTS 
Out of 69 patients 30 were male and 39 were female and mean 
age was 60 years.  
Table 1. Showing gender wise distribution of the patients. 
Gender  No. of Patients  
Male 30 
Female 39 
Total 69 
 
The IOP was noted at day 0 and 1, 3 and 6 months. The 
difference in IOP reduction in two treatment groups from 
baseline to 6 months was the main outcome measure.  
During our study the baseline IOP for dorzolamide + timolol 
group was 25.7 ±4.25 mm Hg and for brimonidine + timolol 
group was 26.3 ±5.86 mm Hg. 
During 6 months treatment the mean reduction in IOP was 
7.83 mm Hg (29.4%) in dorzolamide + timolol group and 9.39 
mm Hg (35.6%) in brimonidine + timolol group. 
The post treatment IOP was 17.87 ±4.25 mm Hg in 
dorzolamide + timolol group and 16.91 ±5.86 mm Hg in 
brimonidine + timolol group. 
 
Table 2. Responder analysis in IOP (mm Hg) reduction 
during 6 months treatment. 
Group Baseline 
IOP 
IOP (mm Hg) change during  
6 months follow up 
 1month  3 
months 
6 months  
Group 1 25.7±4.3 23.0±3.6 20.2±3.7 17.9 ±4.4 
Group 2 26.3 ±5.9 21.3±4.6 18.8±4.6 16.9±5.9 
 
Table 3. Adverse effects during 6 months treatment. 
Gender  No. of Patients  Side effects 
Male 3 
Conjunctival 
congestion  
Female 3 Itching  
Total 6  
DISCUSSION  
This study was designed to compare the efficacy, safety, and 
ocular tolerability of brimonidine-timolol with dorzolamide-
timolol. 
The fixed combination of Brimonidine tartrate 0.2% and 
timolol maleate 0.5% combines a highly selective alpha 2 
adrenergic agonist (Brimonidine) with a nonselective beta 
blocker (timolol)[13].The fixed combination of Dorzolamide 2% 
and timolol maleate 0.5% combines a carbonic anhydrase 
inhibitor dorzolamide) with a nonselective beta blocker 
(timolol). They act by reducing aqueous production and 
enhancing uveo scleral outflow. 
Our study showed that brimonidine + timolol combination has 
superiority over dorzolamide + timolol to reduce the IOP in 
newly diagnosed patients with POAG. 
The value of IOP reduction in our study in brimonidine + 
timolol group was 9.39 mm Hg (35.6%) and 7.83 mm Hg 
(29.4%) in dorzolamide + timolol group. This showed that 
brimonidine + timolol combination is more efficacious in 
reducing the IOP than dorzolamide + timolol combination. 
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Numerous clinical trials have demonstrated the importance of 
IOP lowering in minimizing glaucomatous progressions. Most 
recently, the Canadian Glaucoma Study demonstrated that 
every 1mm Hg rise in IOP was associated with a 19% increase 
in the risk of progression. Therefore, the primary 
consideration in selecting a medical regimen in glaucoma and 
OHT remains achieving maximum IOP lowering to a target 
IOP[7]. For patients who need additional IOP lowering, the 
number of additional medication ideally should be limited as 
the addition of a third or fourth IOP-lowering agent to a 
medication regimen is often unsuccessful for reasons of 
efficacy, safety or compliance. In patients on antiglaucoma 
therapy requiring further IOP reduction, the addition of a 
fixed-combination therapy may provide significant IOP 
lowering while adding only one bottle and two drops to the 
patient’s daily regimen [6]. In this study, both the brimonidine-
timolol fixed combination and the dorzolamide-timolol fixed 
combination provided substantial IOP lowering (29.3% with 
brimonidine-timolol and 23.5% with dorzolamide-timolol). 
CONCLUSION  
Both brimonidine-timolol and dorzolamide-timolol effectively 
lowered IOP in patients with glaucoma or OHT. Better IOP 
reduction and overall ocular comfort was reported in those 
patients on the brimonidine-timolol combination. 
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